Sabrina Serani

Rucaparib receives full FDA approval for treating metastatic castration-resistant prostate cancer, offering a vital chemotherapy-free option for patients.

A groundbreaking trial shows that combining enfortumab vedotin and pembrolizumab enhances survival rates in muscle-invasive bladder cancer patients.

FDA approves a new treatment combining niraparib and abiraterone for BRCA2-mutated metastatic prostate cancer, enhancing patient outcomes.

Remote monitoring enhances infection management in hematologic malignancies, reducing hospitalizations and improving patient communication for better outcomes.

A safety analysis reveals that sacituzumab govitecan and pembrolizumab combination therapy shows manageable side effects in treating metastatic triple-negative breast cancer.

The FDA reviews nivolumab with chemotherapy as a potential new frontline treatment for advanced classical Hodgkin lymphoma, promising improved outcomes.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

Discover the most anticipated breast cancer abstracts at the 2025 San Antonio Symposium, featuring groundbreaking studies in HR+, HER2+, and TNBC.

Pirtobrutinib shows significant improvement in progression-free survival for untreated CLL/SLL, potentially setting a new standard of care.

Linvoseltamab shows promising efficacy and safety as a monotherapy for newly diagnosed multiple myeloma, offering a simpler treatment alternative.

Cilta-cel therapy shows improved outcomes in earlier treatment lines for relapsed/refractory multiple myeloma, enhancing immune fitness and survival rates.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

Oncology and primary care unite to enhance patient care through improved communication and collaboration, addressing the challenges of siloed practices.

Discover the most anticipated abstracts in hematologic malignancies at the 2025 ASH Meeting, featuring groundbreaking studies and innovative therapies.

FDA approves liso-cel, the first CAR T-cell therapy for relapsed marginal zone lymphoma, offering hope for improved patient outcomes.

A novel treatment shows promise for leptomeningeal disease in breast cancer, offering hope with improved survival rates and symptom relief.

Pirtobrutinib receives FDA traditional approval for relapsed CLL, showing significant progression-free survival benefits in clinical trials.

Discover the most anticipated abstracts at the 67th ASH Annual Meeting and Exposition, showcasing groundbreaking research in hematologic malignancies and innovative treatments.

The IsoPSA test revolutionizes prostate cancer diagnosis, enhancing risk assessment and reducing unnecessary biopsies for men with elevated PSA levels.

Axi-cel shows impressive long-term efficacy in treating relapsed/refractory indolent non-Hodgkin lymphoma, with potential curative outcomes for patients.

Sonrotoclax gains FDA priority review for relapsed mantle cell lymphoma, showcasing promising efficacy and safety in challenging patient populations.

A new subcutaneous formulation of toripalimab shows comparable efficacy to the intravenous version, enhancing convenience for lung cancer patients.

FDA approves durvalumab with FLOT chemotherapy for early-stage gastric cancer, showing promising survival rates in recent clinical trials.

Dr Benjamin George champions patient-centered oncology in rural Nebraska, enhancing local cancer care access and fostering community support for patients.

The IGNYTE trial reveals that RP1 combined with nivolumab offers significant, durable responses in advanced melanoma patients previously resistant to anti-PD-1 therapy.

New findings reveal that GDF-15 neutralization with visugromab and nivolumab significantly enhances long-term responses in advanced cancer patients.

High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.

The FDA approves new denosumab biosimilars, expanding treatment options for osteoporosis and cancer-related bone issues, enhancing patient access to care.

Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ED visits and improving treatment adherence through effective symptom management.